Oral invasive procedures in Glanzmann thrombasthenia: a retrospective observational study
2024

Oral Procedures in Patients with Glanzmann Thrombasthenia

Sample size: 21 publication 10 minutes Evidence: high

Author Information

Author(s): Delarue Maxime, Severac François, Soell Martine, Pierre Léa, Desprez Dominique, Bornert Fabien

Primary Institution: University Hospital Strasbourg

Hypothesis

This study evaluates the efficacy and safety of recombinant activated factor VII (rFVIIa) for preventing bleeding during dental procedures in patients with Glanzmann thrombasthenia.

Conclusion

The study supports the efficacy and safety of rFVIIa for preventing bleeding during invasive dental procedures in patients with Glanzmann thrombasthenia.

Supporting Evidence

  • 94% of dental procedures were successful with no major bleeding.
  • Only minor bleeding complications were observed in 6 out of 102 sessions.
  • rFVIIa was administered before dental procedures to prevent bleeding.

Takeaway

Doctors used a special medicine to help patients with a rare bleeding disorder have dental work done without bleeding too much.

Methodology

Data were collected from medical and dental records of patients with Glanzmann thrombasthenia who received rFVIIa for dental procedures.

Potential Biases

Potential biases in patient selection and data collection methods.

Limitations

The study is retrospective and may not account for all variables affecting outcomes.

Participant Demographics

21 patients (10 women, 11 men) aged 8 to 70 years, with a median age of 28.

Statistical Information

P-Value

0.009

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.rpth.2024.102619

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication